NASDAQ, OSIP - OSI Pharmaceuticals Inc.
We are a mid-cap biotechnology company committed to building a scientifically
strong and financially successful top tier biopharmaceutical organization that
discovers, develops and commercializes innovative molecular targeted therapies
addressing major unmet medical needs in oncology, diabetes and obesity.
Our largest area of focus is oncology where our business is anchored by our
flagship product, Tarceva (erlotinib), a small molecule inhibitor of the
epidermal growth factor receptor, or EGFR, which is our primary source of
revenues. In November 2004, Tarceva was approved by the U.S. Food and Drug
Administration, or FDA, for the treatment of advanced non-small cell lung
cancer, or NSCLC, in patients who have failed at least one prior chemotherapy
regimen and, subsequently, in November 2005, for the treatment of patients with
locally advanced and metastatic pancreatic cancer in combination with the
chemotherapy agent, gemcitabine. ...
Read SEC Filing on NASDAQ.com »